Clinical trials: Insulin, completed
Hyperglycemia Steroid-induced
Glucose Control During Glucocorticoid Therapy in Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Purpose of this study is to treat glucocorticoid induced hyperglycemia due to glucocorticoid pulse therapy in a efficacious, safe and convenient way.
- Trial name
- GluCon-COPD (NCT02253121)
- Testing
- Dapagliflozin, Sliding scale insulin
- Where
- 4 sites in Netherlands
- Volunteers
- 46 people
- Sponsor
- Slotervaart Hospital
Non-alcoholic Fatty Liver Disease
Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects
The aim of this study is to explore the effectiveness of liraglutide combined with metformin in non-alcoholic fatty-liver disease patients with type 2 diabetes mellitus (T2DM) compared to sitagliptin and insulin glargine in…
- Trial name
- LIGHT-ON (NCT02147925)
- Testing
- Liraglutide combined with metformin, Insulin glargine combined with metformin, Sitagliptin combined with metformin
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Sun Yat-sen University
Liver Transplantation
Glucose-insulin-potassium Therapy Improves Lactic Acidosis in Liver Transplantation
Lactic acidosis is a common phenomenon occurring during orthotopic liver transplantation (OLT), especially during the anhepatic and early postreperfusion phases.
- Trial name
- GIK (NCT03522181)
- Testing
- saline, Insulin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Central South University
Insulin Secretion
Influence of Central Nervous Insulin Sensitivity on Insulin Secretion
Insulin resistance is a central pathophysiological component of type 2 diabetes and is associated with a high risk of cardiovascular disease. The tissue in which it manifests are mainly muscle, liver, and adipose tissue.
- Trial name
- NCT02870361
- Testing
- intranasal insulin
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Respiratory Distress Syndrome, Adult, Sepsis
Early Insulin and Development of ARDS
Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) is a severe lung condition that causes respiratory failure. Symptoms usually develop within 24 to 48 hours of an original injury or illness, and people with…
- Conditions
- Respiratory Distress Syndrome, Adult, Sepsis, Hyperglycemia
- Trial name
- NCT00605696
- Testing
- Insulin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Albert Einstein College of Medicine
Lymphoma, Diabetes Mellitus, Type 2
Validation of Insulin Protocol for Glucocorticoid-induced Hyperglycemia in Diabetic Oncology Patients
There are no guidelines for the management of glucocorticoid- (henceforth steroid) induced elevated blood sugars (henceforth hyperglycemia).
- Conditions
- Lymphoma, Diabetes Mellitus, Type 2, Hyperglycemia
- Trial name
- NCT02012465
- Testing
- Insulin protocol
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Washington University School of Medicine
Gestational Diabetes Mellitus
Gestational Diabetes: Insulin or Oral Hypoglycemic Agents?
Gestational diabetes mellitus takes place in 2 steps. First, it is the consequence of insulin resistance due to the modifications of the pregnancy hormonal environment, and second, of the deficiency of the beta cells of the…
- Trial name
- DG5 (NCT01215331)
- Testing
- Insulin, Metformin, glyburide and insulin
- Where
- Canada
- Volunteers
- 73 people
- Sponsor
- Université de Sherbrooke
Diabetes Mellitus, Type 2
A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes
The purpose of this study is to compare LY2605541 and human insulin isophane suspension (NPH) using the following measures for participants treated for up to 26 weeks: Change in participants' overall blood sugar control The rate…
- Trial name
- IMAGINE 6 (NCT01790438)
- Testing
- LY2605541, Human Insulin NPH, Oral Antihyperglycemic Medications (OAM)
- Where
- 63 sites in United States, Argentina and 9 more
- Volunteers
- 641 people
- Sponsor
- Eli Lilly and Company
Sarcopenia
Characterizing the Incretin Effect of Amino Acids and Defining GLP-1 Role on Skeletal Muscle
This study has two protocols the aims of which are: 1. To identify age-related effects of AA on incretin secretion and whether and to what extent AA exhibit a true incretin effect (gut- mediated increases in plasma insulin) in…
- Trial name
- Incretin (NCT02370745)
- Testing
- GLP-1, Insulin Actrapid, Oral amino acids
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
Hyperglucagonemia, Obesity
Effects of Glucagon Administration on Energy Expenditure
The purpose of this study is to collect data to help researchers better understand the effects of glucagon on the amount of calories burned.
- Trial name
- GLEE (NCT02237053)
- Testing
- Glucagon, Octreotide, Insulin
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
Diabetes Mellitus, Type 2
Effectiveness of Glucose Control, β Cell Function in Response to Short-term Insulin Pump Therapy in Type 2 Diabetes
The purpose of this study is to investigate and evaluate the significance of intravenous glucose tolerance test in assessment of β-cell function improvement after short course of intensive insulin therapy, trying to illustrate…
- Trial name
- NCT03509324
- Testing
- Insulin LISPRO
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Sun Yat-sen University
Diabetes Mellitus, Type 2
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
The purpose of this study is to compare LY2605541 and insulin glargine using the following measures after participants have been treated for 26 weeks: Change in participants' overall blood sugar control The rate of night time low…
- Trial name
- IMAGINE 5 (NCT01582451)
- Testing
- LY2605541, Insulin glargine
- Where
- 61 sites in United States, Czechia and 7 more
- Volunteers
- 466 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus
A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus
The primary purpose of participation in this study is to compare the safety and efficacy of different dosing schedules of LY2605541 and how different dosing schedules of LY2605541 affect Hemoglobin A1c (HbA1c).
- Trial name
- IMAGINE 7 (NCT01792284)
- Testing
- LY2605541, Insulin Lispro
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 212 people
- Sponsor
- Eli Lilly and Company
Diabetes During Pregnancy
Comparator Trial Using Insulin Glulisine vs. Insulin Lispro for Treatment of Gestational Diabetes
We hypothesize that insulin glulisine is non-inferior to currently proven rapid-acting insulin lispro when used in a basal/bolus regimen to treat hyperglycemia in patients with gestational diabetes mellitus.
- Trial name
- NCT01662921
- Testing
- NPH, Insulin LISPRO, Insulin glulisine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Sansum Diabetes Research Institute
Diabetes Mellitus, Insulin-Dependent
Efficacy Safety and Tolerability of Multiple Doses of Oshadi Icp (Oshadi Oral Insulin) in Patients With Type 1 Diabetes Mellitus - Phase II Clinical Study
Diabetes mellitus (DM) is a chronic disease of carbohydrate, fat, and protein metabolism caused by an absolute or relative deficiency of insulin, an anabolic hormone.
- Conditions
- Diabetes Mellitus, Insulin-Dependent, Type 1
- Trial name
- NCT01973920
- Testing
- Oshadi Icp
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Oshadi Drug Administration
Diabetes Mellitus, Type 1
A Study for Patients With Type 1 Diabetes
Comparison of blood glucose levels in patients with Type 1 diabetes when they take a new basal insulin analog and when they take insulin glargine
- Trial name
- NCT01049412
- Testing
- LY2605541, Insulin glargine
- Where
- 13 sites in United States, Israel
- Volunteers
- 138 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
A Study in Participants With Type I Diabetes Mellitus
The purpose of this study is: To compare blood sugar control on LY2605541 with insulin glargine after 52 weeks of treatment. To compare the rate of nocturnal low blood sugar episodes on LY2605541 with insulin glargine during 52…
- Trial name
- IMAGINE 3 (NCT01454284)
- Testing
- Glargine, LY2605541, Insulin Lispro
- Where
- 119 sites in United States, Australia and 18 more
- Volunteers
- 1,114 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study in Participants With Type 2 Diabetes Mellitus
The purpose of this study is: To compare blood glucose (blood sugar) control on LY2605541 with insulin glargine after 26 weeks of treatment.
- Trial name
- IMAGINE 4 (NCT01468987)
- Testing
- LY2605541, Insulin Glargine, Insulin Lispro
- Where
- 156 sites in United States, Australia and 23 more
- Volunteers
- 1,369 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
A Study in Participants With Type 1 Diabetes Mellitus
The purpose of this study is: To compare the blood sugar control of LY2605541 with insulin glargine after 78 weeks of treatment.
- Trial name
- IMAGINE 1 (NCT01481779)
- Testing
- Glargine, LY2605541, Insulin Lispro
- Where
- 51 sites in United States, Austria and 7 more
- Volunteers
- 455 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study in Patients With Type 2 Diabetes Mellitus
The purpose of this study is: To compare blood sugar control on LY2605541 with insulin glargine after 52 weeks of treatment. To compare the rate of night time low blood sugar episodes on LY2605541 with insulin glargine during 52…
- Trial name
- IMAGINE 2 (NCT01435616)
- Testing
- Glargine, LY2605541
- Where
- 167 sites in United States, Argentina and 21 more
- Volunteers
- 1,538 people
- Sponsor
- Eli Lilly and Company